Weekly Docetaxel and Prednisolone versus Prednisolone Alone in Androgen-Independent Prostate Cancer: A Randomized Phase II Study-Reference-Cited by-同舟云学术

Weekly Docetaxel and Prednisolone versus Prednisolone Alone in Androgen-Independent Prostate Cancer: A Randomized Phase II Study

Published:2007-12 Issue:6 Volume:52 Page:1691-1699
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Fosså Sophie D.,Jacobsen Anne-Birgitte,Ginman Claes,Jacobsen Inga N.,Overn Sissel,Iversen Jon R.,Urnes Thomas,Dahl Alv A.,Veenstra Marijke,Sandstad Berit

Publisher

Elsevier BV

Subject

Urology

Reference24 articles.

1. Chemotherapy in hormone refractory prostate cancer: where do we stand?;Clarke;Eur Urol,2004

2. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European Organization for Research and Treatment of Cancer Genitourinary Group;Fosså;J Clin Oncol,2001

3. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points;Tannock;J Clin Oncol,1996

4. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 Study;Kantoff;J Clin Oncol,1999

5. Feasibility of 21-day continuous infusion of epirubicin in hormone-refractory prostate cancer patents;Berruti;Anticancer Res,2005

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Time trends in systemic treatment for patients with metastatic prostate cancer: a national cohort study;Acta Oncologica;2023-09-19

2. Feasibility of cabazitaxel in octogenarian prostate cancer patients;Current Urology;2022-07-29

3. Survival trends for patients with primary metastatic prostate cancer before and after the introduction of new antitumor drugs;Prostate Cancer and Prostatic Diseases;2021-09-07

4. Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study;European Journal of Cancer;2021-07

5. AN INDIAN PROSPECTIVE STUDY OF DOCETAXEL THERAPY IN CRPC: CAN PRETREATMENT FACTORS PREDICT THE RESPONSE;INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH;2021-05-01